ClinicalTrials.gg
DrugBiological

Lulizumab pegol clinical trials

Also written BMS-931699.

studies test it
5
open now
0
in phase 3
0
first study started
2014

How each study uses lulizumab pegol is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

lulizumab pegol
2
lulizumab
2

Development codes

BMS-931699
5

Studies by the year they started

5 studies that test it; most in 2014 (1)

Studies that test lulizumab pegol, by start year
YearStudies
20141
20161
20171
20191
20221

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
4

Who runs them

Industry 3 · Other 2

Bristol-Myers Squibb (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2)

Often tested with

Tested in the same studies.

BMS-986142 (1)

Studies

Open first, then newest update. How each study uses lulizumab pegol is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 5

Codes

What other systems call lulizumab pegol · ClinicalTrials.gg INT000394

  • MeSH (NLM) C000604694lulizumab pegolOne source NLM
  • UNII (FDA) LCT264LTYELULIZUMAB PEGOLConfirmed FDA, NLM, Wikidata
  • Wikidata Q20706900lulizumab pegolConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C175727Lulizumab PegolOne source FDA
  • DrugBank DB15441One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.